CNS Pharmaceuticals, Inc. (CNSP) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
9/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinCNSP / S&P 100.00% / 15.20% |
LoseCNSP / S&P CNSP unavailable / 15.00% |
LoseCNSP / S&P -108.36% / 50.40% |
| 2026-Q10/3 |
LoseCNSP / S&P -54.48% / -4.33% |
LoseCNSP / S&P CNSP unavailable / 11.30% |
LoseCNSP / S&P -99.21% / 27.70% |
| 2025-Q40/3 |
LoseCNSP / S&P -41.67% / 2.65% |
LoseCNSP / S&P CNSP unavailable / 9.00% |
LoseCNSP / S&P -99.13% / 13.40% |
| 2025-Q30/3 |
LoseCNSP / S&P -9.09% / 8.12% |
LoseCNSP / S&P CNSP unavailable / 4.61% |
LoseCNSP / S&P -102.45% / 13.45% |
| 2025-Q20/3 |
LoseCNSP / S&P -39.34% / 10.94% |
LoseCNSP / S&P CNSP unavailable / 4.83% |
LoseCNSP / S&P -101.62% / 10.63% |
| 2025-Q10/3 |
LoseCNSP / S&P -77.33% / -4.27% |
LoseCNSP / S&P CNSP unavailable / 4.98% |
LoseCNSP / S&P -72.01% / 10.57% |
| 2024-Q40/3 |
LoseCNSP / S&P -8.40% / 2.41% |
LoseCNSP / S&P CNSP unavailable / 5.25% |
LoseCNSP / S&P -61.64% / 6.15% |
| 2024-Q31/3 |
LoseCNSP / S&P -91.71% / 5.89% |
LoseCNSP / S&P CNSP unavailable / 5.89% |
WinCNSP / S&P 15531.81% / 6.11% |
| 2024-Q21/3 |
LoseCNSP / S&P -91.27% / 4.28% |
LoseCNSP / S&P CNSP unavailable / 5.38% |
WinCNSP / S&P 28682.12% / 5.12% |
| 2024-Q11/3 |
LoseCNSP / S&P -71.50% / 10.56% |
LoseCNSP / S&P CNSP unavailable / 5.71% |
WinCNSP / S&P 118045.21% / 5.59% |
| 2023-Q41/3 |
LoseCNSP / S&P 11.40% / 11.69% |
LoseCNSP / S&P CNSP unavailable / 6.81% |
WinCNSP / S&P 110552.58% / 7.78% |
| 2023-Q31/3 |
LoseCNSP / S&P -48.88% / -3.27% |
LoseCNSP / S&P CNSP unavailable / 7.52% |
WinCNSP / S&P 372.37% / -5.03% |
| 2023-Q22/3 |
WinCNSP / S&P 123.00% / 8.74% |
LoseCNSP / S&P CNSP unavailable / 9.50% |
WinCNSP / S&P 184.05% / -8.57% |
| 2023-Q10/3 |
LoseCNSP / S&P -58.33% / 7.50% |
LoseCNSP / S&P CNSP unavailable / 10.77% |
LoseCNSP / S&P -39.52% / -15.69% |
| 2022-Q40/3 |
LoseCNSP / S&P -55.31% / 7.56% |
LoseCNSP / S&P CNSP unavailable / 11.88% |
LoseCNSP / S&P CNSP unavailable / -17.99% |
| 2022-Q30/3 |
LoseCNSP / S&P -36.07% / -4.88% |
LoseCNSP / S&P CNSP unavailable / 13.47% |
LoseCNSP / S&P CNSP unavailable / -1.41% |
| 2022-Q20/3 |
LoseCNSP / S&P -17.89% / -16.10% |
LoseCNSP / S&P CNSP unavailable / 13.71% |
LoseCNSP / S&P CNSP unavailable / 11.04% |
| 2022-Q10/3 |
LoseCNSP / S&P -51.42% / -4.60% |
LoseCNSP / S&P CNSP unavailable / 15.97% |
LoseCNSP / S&P CNSP unavailable / 42.23% |
| 2021-Q40/3 |
LoseCNSP / S&P -52.89% / 11.03% |
LoseCNSP / S&P CNSP unavailable / 15.00% |
LoseCNSP / S&P CNSP unavailable / 96.40% |
| 2021-Q30/3 |
LoseCNSP / S&P -23.98% / 0.58% |
LoseCNSP / S&P CNSP unavailable / 10.77% |
LoseCNSP / S&P CNSP unavailable / 69.42% |
| 2021-Q20/3 |
LoseCNSP / S&P -17.99% / 8.55% |
LoseCNSP / S&P CNSP unavailable / 6.58% |
LoseCNSP / S&P CNSP unavailable / 51.81% |
| 2021-Q11/3 |
WinCNSP / S&P 34.27% / 6.17% |
LoseCNSP / S&P CNSP unavailable / -1.06% |
LoseCNSP / S&P CNSP unavailable / 7.39% |
| 2020-Q40/3 |
LoseCNSP / S&P 1.14% / 12.15% |
LoseCNSP / S&P CNSP unavailable / -3.72% |
LoseCNSP / S&P CNSP unavailable / -33.42% |
| 2020-Q30/3 |
LoseCNSP / S&P -17.76% / 8.93% |
LoseCNSP / S&P CNSP unavailable / -2.04% |
LoseCNSP / S&P CNSP unavailable / -27.10% |
| 2020-Q20/3 |
LoseCNSP / S&P 1.90% / 20.54% |
LoseCNSP / S&P CNSP unavailable / -0.46% |
LoseCNSP / S&P CNSP unavailable / -27.11% |
| 2020-Q10/3 |
LoseCNSP / S&P -46.84% / -19.60% |
LoseCNSP / S&P CNSP unavailable / 3.47% |
LoseCNSP / S&P CNSP unavailable / -14.75% |
| 2019-Q40/3 |
LoseCNSP / S&P CNSP unavailable / 9.07% |
LoseCNSP / S&P CNSP unavailable / 5.36% |
LoseCNSP / S&P CNSP unavailable / 2.99% |
| 2019-Q30/3 |
LoseCNSP / S&P CNSP unavailable / 1.70% |
LoseCNSP / S&P CNSP unavailable / 5.02% |
LoseCNSP / S&P CNSP unavailable / 0.21% |
| 2019-Q20/3 |
LoseCNSP / S&P CNSP unavailable / 4.30% |
LoseCNSP / S&P CNSP unavailable / 6.64% |
LoseCNSP / S&P CNSP unavailable / 8.65% |
| 2019-Q10/3 |
LoseCNSP / S&P CNSP unavailable / 13.65% |
LoseCNSP / S&P CNSP unavailable / 8.12% |
LoseCNSP / S&P CNSP unavailable / 14.29% |
| 2018-Q40/3 |
LoseCNSP / S&P CNSP unavailable / -13.52% |
LoseCNSP / S&P CNSP unavailable / 9.05% |
LoseCNSP / S&P CNSP unavailable / 18.23% |
| 2018-Q30/3 |
LoseCNSP / S&P CNSP unavailable / 7.71% |
LoseCNSP / S&P CNSP unavailable / 10.21% |
LoseCNSP / S&P CNSP unavailable / 19.06% |
| 2018-Q20/3 |
LoseCNSP / S&P CNSP unavailable / 3.43% |
LoseCNSP / S&P CNSP unavailable / 9.03% |
LoseCNSP / S&P CNSP unavailable / 14.46% |
| 2018-Q10/3 |
LoseCNSP / S&P CNSP unavailable / -0.76% |
LoseCNSP / S&P CNSP unavailable / 7.68% |
LoseCNSP / S&P CNSP unavailable / 12.46% |
| 2017-Q40/3 |
LoseCNSP / S&P CNSP unavailable / 6.64% |
LoseCNSP / S&P CNSP unavailable / 7.03% |
LoseCNSP / S&P CNSP unavailable / 13.82% |
| 2017-Q30/3 |
LoseCNSP / S&P CNSP unavailable / 4.48% |
LoseCNSP / S&P CNSP unavailable / 5.68% |
LoseCNSP / S&P CNSP unavailable / 17.57% |
| 2017-Q20/3 |
LoseCNSP / S&P CNSP unavailable / 3.09% |
LoseCNSP / S&P CNSP unavailable / 4.83% |
LoseCNSP / S&P CNSP unavailable / 17.74% |
| 2017-Q10/3 |
LoseCNSP / S&P CNSP unavailable / 6.07% |
LoseCNSP / S&P CNSP unavailable / 3.67% |
LoseCNSP / S&P CNSP unavailable / 13.32% |
| 2016-Q40/3 |
LoseCNSP / S&P CNSP unavailable / 3.82% |
LoseCNSP / S&P CNSP unavailable / 2.09% |
LoseCNSP / S&P CNSP unavailable / 7.05% |
| 2016-Q30/3 |
LoseCNSP / S&P CNSP unavailable / 3.85% |
LoseCNSP / S&P CNSP unavailable / 0.20% |
LoseCNSP / S&P CNSP unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CNSP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -11.02% | 20.78% |
| Annualized return | -11.02% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CNSP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 83.14% |
| Annualized return | -91.78% | 12.86% |
10Y · 2019-11-08 to 2026-08-27
| Metric | CNSP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -74.13% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |